Nucleic Acid Therapy Accelerator (NATA)

The Nucleic Acid Therapy Accelerator (NATA) is a newly established, independent, not-for-profit Medical Research Council (MRC) Unit – part of UK Research and Innovation (UKRI). Our mission is to advance the development of nucleic acid therapies and associated technologies through high-quality science, collaborations and interdisciplinary research.

We work with academics, clinicians, business and charities, bringing together a diverse network of expertise, skills and innovative technologies to bridge translational gaps in nucleic acid therapy development.

Our initial therapeutic focus is the application of antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs).

We have a unique, multidisciplinary skill set spanning chemistry, biology and pre-clinical testing. Our capabilities include oligonucleotide design, novel chemical modifications, advanced conjugation chemistry, cell- and tissue-specific targeting, developing 3-D cell models and applying in vivo tools to assess efficacy and safety.

We have a flexible approach to collaborations and partnership, developing bespoke solutions to meet the aims and needs or our collaborators and projects. We can provide end-to-end support for projects from a genetic target to pre-clinical proof-of-concept, or can collaborate on a specific part of the translational pipeline.

We are actively seeking new partnerships and collaborators. Contact us to discuss how we can work together.